Anderson, MD, MAS, an assistant professor of medicine from the University of Pittsburgh, clinical trials of several GLP-1 receptor agonists like semaglutide (Wegovy/Ozempic, Novo Nordisk) for weight loss included exclusion criteria of chronic medical and psychiatric conditions. However, [FDA] labeling does not restrict these treatments in these populations, they wrote in JAMA Internal Medicine
The real danger of lipohypertrophy is not the lumps themselves
If you shake hard enough, you can actually see the solution become cloudy or foamy, which is a visible sign of peptide degradation
Prioritize protein over carbs or fat at every snack protein is the hardest macronutrient to get enough of on a GLP-1-suppressed appetite
What Is NAD+ and Why Does It Matter
Dispose used syringes in sharps container